Pages that link to "Q44381576"
Jump to navigation
Jump to search
The following pages link to Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer (Q44381576):
Displaying 50 items.
- [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung (Q24550866) (← links)
- Functional imaging biomarkers for assessing response to treatment in liver and lung metastases (Q26860708) (← links)
- Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis (Q27003737) (← links)
- The use and misuse of positron emission tomography in lung cancer evaluation (Q27021838) (← links)
- ¹⁸F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data (Q30980315) (← links)
- Contrast-enhanced CT- and MRI-based perfusion assessment for pulmonary diseases: basics and clinical applications (Q31121660) (← links)
- [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study (Q33235431) (← links)
- Recent chemotherapy reduces the maximum-standardized uptake value of 18F-fluoro-deoxyglucose positron emission tomography in colorectal cancer. (Q33633649) (← links)
- A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy (Q33664774) (← links)
- 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response (Q33904549) (← links)
- Broadening the scope of image-guided radiotherapy (IGRT). (Q33943514) (← links)
- 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy (Q33973367) (← links)
- (18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy (Q33973399) (← links)
- Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST (Q34023973) (← links)
- Tumour response evaluation with fluorodeoxyglucose positron emission tomography: research technique or clinical tool? (Q34256387) (← links)
- Molecular imaging in cancer treatment (Q34496670) (← links)
- The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy (Q34720945) (← links)
- Positron Emission Tomography (PET) in Oncology (Q34774840) (← links)
- Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). (Q34898391) (← links)
- From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors (Q34978457) (← links)
- Neoadjuvant chemotherapy and chemoradiotherapy for non-small cell lung cancer: current status and future prospects (Q35143926) (← links)
- The role of PET in monitoring therapy (Q35172974) (← links)
- FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. (Q35208087) (← links)
- Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer (Q35445146) (← links)
- Appropriateness criteria of FDG PET/CT in oncology (Q35568776) (← links)
- Positron emission tomography scanning for the diagnosis and management of lung cancer (Q35617157) (← links)
- Positron emission tomography in the management of non-small cell lung cancer (Q35684131) (← links)
- Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy. (Q35827602) (← links)
- Role of FDG-PET in the diagnosis and management of lung cancer (Q35843677) (← links)
- Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. (Q35874704) (← links)
- Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma (Q35911195) (← links)
- Metabolic response assessment with (18)F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer (Q36024114) (← links)
- Does early PET/CT assesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer? (Q36154024) (← links)
- FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy (Q36239986) (← links)
- Computerized PET/CT image analysis in the evaluation of tumour response to therapy (Q36295403) (← links)
- Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer (Q36327908) (← links)
- Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer (Q36341962) (← links)
- The contribution of PET/CT to improved patient management (Q36371912) (← links)
- Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology (Q36420719) (← links)
- Monitoring chemotherapy and radiotherapy of solid tumors (Q36474962) (← links)
- [F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients. (Q36490370) (← links)
- Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer (Q36516767) (← links)
- Targeted molecular imaging in oncology: focus on radiation therapy (Q36528175) (← links)
- Multimodality therapy for Pancoast tumor (Q36586494) (← links)
- Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial (Q36616213) (← links)
- Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. (Q36661461) (← links)
- Functional PET imaging in cancer drug development (Q36768305) (← links)
- Stage I non-small cell lung cancer: results for surgery in a patterns-of-care study in Sydney and for high-dose concurrent end-phase boost accelerated radiotherapy. (Q36780656) (← links)
- Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer. (Q36815636) (← links)
- The prognostic value of PET and PET/CT in cervical cancer (Q36836254) (← links)